Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EPS (Basic): 2022-2025

Historic EPS (Basic) for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to -$0.94.

  • Axsome Therapeutics' EPS (Basic) rose 29.85% to -$0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.67, marking a year-over-year increase of 29.03%. This contributed to the annual value of -$5.99 for FY2024, which is 13.66% down from last year.
  • Latest data reveals that Axsome Therapeutics reported EPS (Basic) of -$0.94 as of Q3 2025, which was up 3.09% from -$0.97 recorded in Q2 2025.
  • Axsome Therapeutics' EPS (Basic)'s 5-year high stood at -$0.26 during Q1 2023, with a 5-year trough of -$2.13 in Q4 2023.
  • In the last 3 years, Axsome Therapeutics' EPS (Basic) had a median value of -$1.34 in 2024 and averaged -$1.31.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 74.76% in 2023, then plummeted by 453.85% in 2024.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' EPS (Basic) stood at -$1.43 in 2022, then tumbled by 48.95% to -$2.13 in 2023, then increased by 27.70% to -$1.54 in 2024, then rose by 29.85% to -$0.94 in 2025.
  • Its EPS (Basic) was -$0.94 in Q3 2025, compared to -$0.97 in Q2 2025 and -$1.22 in Q1 2025.